Posted by Michael Wonder on 26 Dec 2021
GSK’s Jemperli (dostarlimab for injection) approved in Canada as an anti-PD-1 therapy for recurrent or advanced endometrial cancer
15 December 2021 - GSK announces today that it has been granted Notice of Compliance with conditions for its endometrial cancer treatment Jemperli (dostarlimab for injection) by Health Canada.
As an anti-PD-1 therapy for recurrent or advanced endometrial cancer approved in Canada, Jemperli is indicated as a monotherapy for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high recurrent or advanced endometrial cancer, that has progressed on or following prior treatment with a platinum containing regimen.
